Literature DB >> 31781782

[Changes in the treatment of metastatic prostate cancer-new data and open questions].

P Albers1, M Bögemann2, S Machtens3, A S Merseburger4, M Schostak5, T Steuber6, C Wülfing7, M De Santis8.   

Abstract

The availability of taxane-based chemotherapy and androgen-receptor-targeted agents (ARTAs) have significantly broadened the therapeutic options for patients with metastatic prostate cancer and may also result in longer patient survival. The therapeutic sequence of ARTAs and taxanes may influence outcome and therefore decisions should be made on an individual basis. This article provides guidance for therapeutic decision-making in daily clinical practice by working out criteria that can be used to support individual therapeutic decisions. The focus is on metastatic castration-naive prostate cancer, oligometastatic disease as well as non-metastatic and metastatic castration-resistant prostate cancer.

Entities:  

Keywords:  Androgen receptor; Chemotherapy; Oligometastases; Prostatic neoplasms, castration-naive; Systemic therapy

Mesh：

Substances：

Year:  2020        PMID： 31781782     DOI： 10.1007/s00120-019-01072-0

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  29 in total

Review 1.  Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer.

Authors:  Francesca Maines; Orazio Caffo; Antonello Veccia; Chiara Trentin; Giampaolo Tortora; Enzo Galligioni; Emilio Bria
Journal:  Crit Rev Oncol Hematol       Date:  2015-08-01       Impact factor: 6.312

2.  Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

Authors:  Mario Eisenberger; Anne-Claire Hardy-Bessard; Choung Soo Kim; Lajos Géczi; Daniel Ford; Loïc Mourey; Joan Carles; Phillip Parente; Albert Font; Gabriel Kacso; Mustapha Chadjaa; Wenping Zhang; John Bernard; Johann de Bono
Journal:  J Clin Oncol       Date:  2017-08-15       Impact factor: 44.544

3.  Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Authors:  Matthew R Smith; Fred Saad; Simon Chowdhury; Stéphane Oudard; Boris A Hadaschik; Julie N Graff; David Olmos; Paul N Mainwaring; Ji Youl Lee; Hiroji Uemura; Angela Lopez-Gitlitz; Géralyn C Trudel; Byron M Espina; Youyi Shu; Youn C Park; Wayne R Rackoff; Margaret K Yu; Eric J Small
Journal:  N Engl J Med       Date:  2018-02-08       Impact factor: 91.245

4.  Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

Authors:  Maha Hussain; Karim Fizazi; Fred Saad; Per Rathenborg; Neal Shore; Ubirajara Ferreira; Petro Ivashchenko; Eren Demirhan; Katharina Modelska; Andrew Krivoshik; Cora N Sternberg
Journal:  N Engl J Med       Date:  2018-06-28       Impact factor: 91.245

5.  Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.

Authors:  Chad G Rusthoven; Bernard L Jones; Thomas W Flaig; E David Crawford; Matthew Koshy; David J Sher; Usama Mahmood; Ronald C Chen; Brian F Chapin; Brian D Kavanagh; Thomas J Pugh
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

6.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

7.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Authors:  Nicholas D James; Johann S de Bono; Melissa R Spears; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Alastair W S Ritchie; Claire L Amos; Clare Gilson; Rob J Jones; David Matheson; Robin Millman; Gerhardt Attard; Simon Chowdhury; William R Cross; Silke Gillessen; Christopher C Parker; J Martin Russell; Dominik R Berthold; Chris Brawley; Fawzi Adab; San Aung; Alison J Birtle; Jo Bowen; Susannah Brock; Prabir Chakraborti; Catherine Ferguson; Joanna Gale; Emma Gray; Mohan Hingorani; Peter J Hoskin; Jason F Lester; Zafar I Malik; Fiona McKinna; Neil McPhail; Julian Money-Kyrle; Joe O'Sullivan; Omi Parikh; Andrew Protheroe; Angus Robinson; Narayanan N Srihari; Carys Thomas; John Wagstaff; James Wylie; Anjali Zarkar; Mahesh K B Parmar; Matthew R Sydes
Journal:  N Engl J Med       Date:  2017-06-03       Impact factor: 91.245

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.

Authors:  Piet Ost; Dries Reynders; Karel Decaestecker; Valérie Fonteyne; Nicolaas Lumen; Aurélie De Bruycker; Bieke Lambert; Louke Delrue; Renée Bultijnck; Tom Claeys; Els Goetghebeur; Geert Villeirs; Kathia De Man; Filip Ameye; Ignace Billiet; Steven Joniau; Friedl Vanhaverbeke; Gert De Meerleer
Journal:  J Clin Oncol       Date:  2017-12-14       Impact factor: 44.544

10.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

Authors:  Christos E Kyriakopoulos; Yu-Hui Chen; Michael A Carducci; Glenn Liu; David F Jarrard; Noah M Hahn; Daniel H Shevrin; Robert Dreicer; Maha Hussain; Mario Eisenberger; Manish Kohli; Elizabeth R Plimack; Nicholas J Vogelzang; Joel Picus; Matthew M Cooney; Jorge A Garcia; Robert S DiPaola; Christopher J Sweeney
Journal:  J Clin Oncol       Date:  2018-01-31       Impact factor: 50.717
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.